CERC - Cerecor Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.1955
-0.1445 (-4.33%)
As of 2:23PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.3400
Open3.3400
Bid3.1800 x 1300
Ask3.2100 x 800
Day's Range3.1600 - 3.3800
52 Week Range2.7100 - 7.6500
Volume65,583
Avg. Volume148,089
Market Cap150.073M
Beta (3Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-1.0540
Earnings DateNov 11, 2019 - Nov 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.67
Trade prices are not sourced from all markets
  • MarketWatch

    Cerecor stock soars 17% premarket after FDA grants fast-track designation to treatment for rare disorder

    Shares of Cerecor Inc. rallied 17.5% in premarket trade Wednesday, after the biotech said the U.S. Food and Drug Administration has awarded it an expedited review process for a treatment for Mannose-Phosphate Isomerase Deficiency, or MPI-CDG, a rare metabolic disorder. The FDA has granted Rockville, Md.-based Cerecor Fast Trace Designation for its CERC-802 treatment, an oral formulation of D-mannose. CERC-802 is an ultra-pure formulation of D-mannose, a naturally occurring monosaccharide that is found in animals, microorganisms, and plants, including edible fruits and herbs. "CDG patients are born with a genetic defect that hinders their ability to utilize certain monosaccharides in the production of glycoproteins," the company explained. Shares have gained 19% in 2019, while the S&P 500 has gained 16%.

  • GlobeNewswire

    Cerecor Receives Fast Track Designation from FDA for CERC-802 for the Treatment of Mannose-Phosphate Isomerase Deficiency

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CERC-802, an ultra-pure, oral formulation of D-mannose currently in development for the treatment of Mannose-Phosphate Isomerase Deficiency, also known as MPI-CDG or CDG-1b.

  • GlobeNewswire

    Cerecor Reports Second Quarter 2019 Results

    -Positive Final Results with CERC-301 in nOH-First Patient Enrolled in CDG FIRST Trial- FDA Acceptance of IND Application of CERC-802 ROCKVILLE, Md., Aug. 08, 2019 -- Cerecor.

  • GlobeNewswire

    FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-802 for the treatment of MPI-CDG

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has received notification from the U.S. Food and Drug Administration (FDA), stating that the FDA has accepted the CERC-802 MPI deficiency Investigational New Drug (IND) application filing and the proposed study can begin immediately. CERC-802, an ultra-pure, oral formulation of D-mannose is currently in development for the treatment of Mannose Phosphate Isomerase (MPI) Deficiency, also known as MPI-CDG or CDG-1b.

  • What Does Cerecor Inc.'s (NASDAQ:CERC) Balance Sheet Tell Us About It?
    Simply Wall St.

    What Does Cerecor Inc.'s (NASDAQ:CERC) Balance Sheet Tell Us About It?

    While small-cap stocks, such as Cerecor Inc. (NASDAQ:CERC) with its market cap of US$191m, are popular for their...

  • Zacks Small Cap Research

    CERC: CDG FIRST Trial Underway…

    By David Bautz, PhD NASDAQ:CERC READ THE FULL CERC RESEARCH REPORT Business Update CDG FIRST Trial Underway On July 15, 2019, Cerecor Inc. (NASDAQ:CERC) announced the first patient has been enrolled in ...

  • GlobeNewswire

    Cerecor Announces First Patient Enrolled in CDG FIRST Trial

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced it has enrolled its first patient into the CDG FIRST (Congenital Disorders of Glycosylation Formative Retrospective Study) trial. The CDG FIRST trial is a multi-center, international, non-interventional, retrospective study that follows general principles of periodic assessment of CDG patients in routine practice.  The objectives of the study are to collect natural history and treatment-related data of patients diagnosed with PGM1-CDG, MPI-CDG or SLC35C1-CDG who are either treated with or without D-galactose, D-mannose and L-fucose, respectively, as well as patients with other CDGs who are treated with one of the sugars.

  • GlobeNewswire

    Cerecor Announces Positive Final Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (OH)

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced positive results from its completed Phase I study of CERC-301, being developed for the treatment of neurogenic orthostatic hypotension (nOH).

  • Benzinga

    18 Stocks Joining The Russell Indices

    The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...

  • GlobeNewswire

    Cerecor Added to Russell 3000® Index

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced that it has been added to the Russell 3000® Index effective after the U.S. market opens on July 1, 2019. Membership in the Russell 3000® Index, which remains in place for one year, means the automatic inclusion of Cerecor’s common stock in index funds designed to track stocks included in the Russell 3000® Index.

  • GlobeNewswire

    Cerecor Appoints Keith Schmidt to its Board of Directors

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced the appointment of Keith Schmidt to its Board of Directors effective immediately.  Mr. Schmidt joins the Cerecor Board as a member of the Audit Committee, the Compensation Committee, and an independent director serving a term ending at the 2019 Annual Meeting.

  • GlobeNewswire

    Cerecor Set to Join Russell 3000® Index

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced that it is set to join the Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the U.S. market opens on July 1, 2019, according to a preliminary list of additions posted June 7, 2019. Membership in the Russell 3000® Index, which remains in place for one year, means the automatic inclusion of Cerecor’s common stock in index funds designed to track stocks included in the Russell 3000® Index. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

  • Zacks Small Cap Research

    CERC: Completion of Phase 1 Trial of CERC-801…

    On April 29, 2019, Cerecor Inc. (CERC) announced dosing has completed in the Phase 1 clinical trial of CERC-801 (D-galactose), which is being developed for the treatment of Phosphoglucomutase 1 (PGM1) deficiency. The open label, randomized, single dose, 4-way crossover study in 16 healthy adult volunteers showed CERC-801 to be safe and well tolerated with no reports of serious adverse events. The company has also initiated a natural history study to collect efficacy and safety data from CDG patients treated with monosaccharide replacement therapy, which will be an important part of the application for approval using the 505(b)(2) pathway.

  • GlobeNewswire

    Cerecor Reports First Quarter 2019 Results

    - Positive interim results from the Phase l study of CERC-301 in nOH -Positive results from Phase I Safety Data for CERC-801 in Healthy Volunteers ROCKVILLE, Md., May 09,.

  • Introducing Cerecor (NASDAQ:CERC), A Stock That Climbed 42% In The Last Three Years
    Simply Wall St.

    Introducing Cerecor (NASDAQ:CERC), A Stock That Climbed 42% In The Last Three Years

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Vanguard founder Jack Bogle helped spearhead the low-cost index fund, putting average returns w...

  • GlobeNewswire

    Cerecor Announces Positive Phase I Safety Data for CERC-801 in Healthy Volunteers

    ROCKVILLE, Md., April 29, 2019 -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for.

  • Zacks Small Cap Research

    CERC: Positive Results for Phase 1 Trial of CERC-301…

    The Phase 1 trial is a double blind, randomized, placebo controlled trial with a target enrollment of 20 Parkinson’s patients with nOH. Each patient will have five visits in which they will receive four single escalating doses of drug (8, 12, 16, or 20 mg) or placebo.

  • ACCESSWIRE

    Cerecor Announces Positive Interim Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (nOH)

    ROCKVILLE, MD / ACCESSWIRE / April 15, 2019 / Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced positive interim results from the Phase I study of CERC-301, an NMDA receptor antagonist, being developed for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in Parkinson's Disease. CERC-301 is an orally available, NR2B-specific, NMDA receptor antagonist being developed for the treatment of symptomatic neurogenic orthostatic hypotension (nOH).

  • ACCESSWIRE

    Cerecor Announces Leadership Changes

    Dr. Simon Pedder, Ph.D. has been appointed Executive Chairman of the Board. As well, Patrick Crutcher has been promoted to Chief Strategy Officer. Peter Greenleaf will transition from the CEO role but remain on the Board of Directors, including providing strategic assistance during the transition.

  • Zacks Small Cap Research

    CERC: Multiple Data Readouts in 2019; Commercial Unit Continues Growth…

    Cerecor, Inc. (CERC) is a fully integrated biopharmaceutical company with commercial operations intended to support the development of a pipeline of therapies targeting neurology, pediatric, and orphan indications. The neurology pipeline is led by CERC-301, which is currently in a Phase 1 clinical trial in patients with neurogenic orthostatic hypotenstion (nOH). Cerecor is currently conducting a Phase 1 clinical trial of its lead neurology candidate CERC-301 for the treatment of nOH associated with Parkinson’s disease and other neurodegenerative diseases.

  • ACCESSWIRE

    Cerecor Reports Fourth Quarter and Full Year 2018 Results

    -Significant Advancement in Pipeline and Regulatory Milestones -Meets Increased 2018 Revenue Guidance -Announces Net Revenue Guidance of $20-22 Million for 2019 ROCKVILLE, MD / ACCESSWIRE / March 18, 2019 ...

  • ACCESSWIRE

    Cerecor Increases Previously Announced Bought Deal of Common Stock to $10 Million

    ROCKVILLE, MARYLAND / ACCESSWIRE / March 6, 2019 / Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 1,818,182 shares of common stock of the Company, at a price to the public of $5.50 per share (the "Public Price"). The Company also has granted to the underwriter a 45-day option to purchase up to an additional 272,727 shares of common stock at the Public Price.

  • ACCESSWIRE

    Cerecor Announces $8 Million Bought Deal Offering

    ROCKVILLE MD / ACCESSWIRE / March 5, 2019 / Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis a minimum of 1,454,546 shares of common stock of the Company, at a price to the public of $5.50 per share (the "Public Price"). H.C. Wainwright & Co. is acting as the sole book-running manager for the offering. The Company also has granted to the underwriter a 45-day option to purchase up to an additional 218,181 shares of common stock at the Public Price.

  • Do Insiders Own Lots Of Shares In Cerecor Inc. (NASDAQ:CERC)?
    Simply Wall St.

    Do Insiders Own Lots Of Shares In Cerecor Inc. (NASDAQ:CERC)?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Every investor in Cerecor Inc. (NASDAQ:CERC) should be aware ofRead More...

  • Drugmakers raised prices of over 40 prescription drugs
    Yahoo Finance Video

    Drugmakers raised prices of over 40 prescription drugs

    Yahoo Finance’s Adam Shapiro, Sibile Marcellus, and Rick Newman join Direxion Managing Director Sylvia Jablonski to discuss.